Highlights Innate Pharma

Equities

IPH

FR0010331421

Market Closed - Euronext Paris Other stock markets 11:35:28 2024-04-26 am EDT			5-day change	1st Jan Change
2.245 ^EUR	+2.98%		+6.40%	-14.31%

Apr. 15	Sanofi: progress in hematology trial	CF
Apr. 15	Innate Pharma: progress in hematology trial	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sanofi: progress in hematology trial	Apr. 15	CF
Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients	Apr. 15	CI
Innate Pharma: IPH45 data presented at AACR	Apr. 10	CF
Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate	Apr. 10	CI
Innate Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Innate Pharma initiates lymphoma trial	Mar. 06	CF
Innate Pharma: abstract on IPH45 at the AACR congress	Mar. 06	CF
Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin?s Lymphoma	Mar. 06	CI
Innate Pharma Says FDA Lifted Partial Clinical Hold on Lacutamab Clinical Program	Jan. 04	MT
Innate Pharma: FDA suspension lifted	Jan. 04	CF
Sanofi Exercises Option to License 4th NK Cell Engager Program in Solid Tumors From Innate Pharma's ANKET Platform	Dec. 19	MT
Sanofi Exercises Option to License 4th NK Cell Engager Program in Solid Tumors From Innate Pharma's ANKET Platform	Dec. 19	MT
Sanofi Licenses Natural Killer Cell Engager Program from Innate Pharma	Dec. 19	MT
Innate Pharma S.A. and Sanofi Announce Licensing of Fourth Natural Killer Cell Engager in Oncology to Sanofi	Dec. 19	CI
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023	Dec. 10	CI
Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023	Nov. 03	CI
Innate Pharma Says Trials of Lymphoma Therapy Placed on Partial Clinical Hold After Patient Death	23-10-05	MT
Innate Pharma S.A. Provides Update on Lacutamab Clinical Program	23-10-05	CI
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023	23-09-22	CI
Innate Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Innate Pharma

Equities

IPH

FR0010331421

Highlights

Filters